Navigation Links
Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community
Date:12/5/2007

stitutional and governmental purchasers), economic conditions such as interest rate and currency exchange rate fluctuations, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and healthcare reform, pharmaceutical rebates and reimbursement, claims and concerns that may arise regarding the safety and efficacy of in-line products and product candidates, changes to wholesaler inventory levels, variability in data provided by third parties, changes in, and interpretation of, governmental regulations and legislation affecting domestic or foreign operations, including tax obligations, difficulties and delays in product development, manufacturing or sales, patent positions and the ultimate outcome of any litigation matter, including whether Apotex will prevail in its appeal of the District court's decision in the PLAVIX(R) patent litigation. These factors also include the company's ability to execute successfully its strategic plans, including its Productivity Transformation Initiative and any significant acquisitions and divestitures, the expiration of patents on certain other products, and the impact and result of governmental investigations. There can be no guarantees with respect to pipeline products that future clinical studies will support the data described in this release, that the products will receive necessary regulatory approvals, or that they will prove to be commercially successful; nor are there guarantees that regulatory approvals will be sought, or sought within currently expected timeframes, or that contractual milestones will be achieved. For further details and a discussion of these and other risks and uncertainties, see the company's periodic reports, including current reports on Form 8-K, quarterly reports on Form 10-Q and the annual report on Form 10-K, furnished to and filed with the Securities and Exchange Commission. The company undertakes no obligation to publicly update any forward-looking statement, whether a
'/>"/>
SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
2. Bristol-Myers Squibb to Acquire Adnexus Therapeutics
3. Aureus Pharma Announces Renewal and Expansion of Licensing Agreement With Bristol-Myers Squibb for its AurSCOPE Knowledge Databases
4. Bristol-Myers Squibb and Pierre Fabre Provide Update On Vinflunine Development Status
5. GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
6. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
7. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
8. Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business
9. Kendle Marks 10th Anniversary as Public Company With NASDAQ Opening Bell Ceremony and Investor Day Event
10. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
11. Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... have succeeded in measuring vibrational motion of a single ... how vibration of a single molecule differs from the ... was performed at the University of California, Irvine, where ... works as a visiting fellow under professor Vartkess A. ... team was lead by Professor Eric O. Potma. The ...
(Date:8/20/2014)... Francisco, CA (PRWEB) August 20, 2014 ... Conference is being held on October 29-30 in ... perspectives from industry, academic and government researchers and clinicians ... in the space. , In the twelve years ... one hundred therapies have been introduced with pharmacogenetic information ...
(Date:8/20/2014)... GraphDB™ 6.0 from ... to the enterprise replication cluster, faster loading speeds, ... and Elasticsearch. This release happens to coincide with ... – GraphDB™ was formerly known as OWLIM. ... mature enterprise resilient RDF triplestore will also benefit ...
(Date:8/19/2014)... 19, 2014 Cellgen Diagnostics ... $200,000 to fund a corporate lab for its ... This development is a critical component in the ... to the implementation of personalized medicine – a ... medicine. , Indiegogo contributions will support Cellgen’s intent ...
Breaking Biology Technology:Seeing a molecule breathe 26th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3
... Calif., Oct. 5 Bionovo, Inc.,(Nasdaq: BNVI ), a ... in the areas of women,s health and cancer, today announced,that ... at the 4th,Annual BIO Investor Forum. The presentation will ... the Palace Hotel in San Francisco, CA. A live ...
... Cerimon,Pharmaceuticals, Inc., today announced Paul Sekhri, Cerimon,s ... 2007 BIO Investor Forum on,Thursday, October 11, 2007, ... in San,Francisco. The presentation will take place in ... Cerimon Pharmaceuticals, Inc. is a biopharmaceutical company ...
... Coalition for a,Competitive Pharmaceutical Market (CCPM) issued the ... announcement regarding its,"Generic Initiative for Value and Efficiency" ... grappling with,how to manage escalating prescription drug costs, ... focus on ways to enhance timely generic access.,Today,s ...
Cached Biology Technology:CCPM Issues Statement on FDA's GIVE Initiative 2
(Date:8/19/2014)... Aug. 19, 2014 To improve students, chances ... grades, the University of Houston (UH) implemented a ... students at risk for failure. , Through ... Board (THECB), the Department of Biology and Biochemistry ... students taking "General Biology" for non-majors and "Introductory ...
(Date:8/19/2014)... of the world, leprosy and tuberculosis live side-by-side. ... leprosy per year, with nearly all of them ... century-old vaccine Bacille Calmette-Guerin, or BCG, provides only ... a more potent vaccine is needed to combat ... stronger weapon against both diseases., In a study ...
(Date:8/19/2014)... Aug. 19, 2014 ) -- Scientists at the Houston ... up and transfer single cells using a pipette -- ... describe this engineering feat and preliminary test results in ... American Chemical Society . , "Studying single cells and ... biomedical research," said nanomedicine department. faculty member Lidong Qin, ...
Breaking Biology News(10 mins):University of Houson program earns kudos for improving grades, retaining students 2University of Houson program earns kudos for improving grades, retaining students 3New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2Moving single cells around -- accurately and cheaply 2
... century, scientists have struggled with plutonium contamination spreading further ... in humans and animals. It was known nanometer ... no one had been able to study its structure ... groundwater. Scientists at the U.S. Department of ...
... Spanish flu outbreak of 1918 killed between 30 and ... cause of death was acute respiratory distress syndrome (ARDS). ... body during which the lung becomes severely damaged. ARDS ... but also by chemical agents. These could be toxic ...
... the most common cause of episodic headache, and by ... visit. It affects some 15% of the population, including ... considerable burden on healthcare in both the developed and ... years, great strides have been made in discovering common ...
Cached Biology News:Scientists discover how nanocluster contaminants increase risk of spreading 2New strategies against bird flu 2Concentrating on different aspects of pain leads to breakthrough in migraine genetics 2
High affinity antibody reacting with S-100 ab heterodimer. Could be used for Western blotting application and immunoassay....
... (g/L):,Tryptone, 10 ,Yeast extract, 5 ,Sodium ... ,Ferric ammonium citrate, 0.5 ,IPTG, 0.03 ... soluble, autoclavable chromogenic substrate for -galactosidase. ... -galactosidase generates a black insoluble precipitate. ...
S-100 alpha/beta chain (8B10)...
SCCRO (S-17)...
Biology Products: